Propanc Biopharma, Inc. 8-K

What Happened

• Propanc Biopharma, Inc. announced it received a written notice from Nasdaq on December 31, 2025 stating the company is not in compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement, based on the prior 35 consecutive business days. The notice does not trigger immediate delisting.
• Nasdaq has given the company a 180-calendar-day compliance period to regain compliance, making the deadline June 30, 2026. To regain compliance the common stock must close at or above $1.00 for at least ten consecutive business days. If the company fails to regain compliance, it may be eligible for a second 180-day period if it meets other listing requirements and notifies Nasdaq of an intent to cure the deficiency (for example, via a reverse stock split). The company says it will monitor the closing bid price and consider options to regain compliance.

Key Details

• Notice date: December 31, 2025; Nasdaq rule cited: Listing Rule 5550(a)(2) ($1.00 minimum bid).
• Initial compliance period: 180 days; compliance deadline: June 30, 2026.
• Regain standard: $1.00 closing bid for 10 consecutive business days; possible additional 180-day extension if other listing requirements are met and the company files intent to cure.
• Potential impacts listed by the company if delisted: reduced liquidity and share price, fewer investors, hindered ability to raise equity, limited use of registration statements, and impaired equity incentive programs.

Why It Matters

• For investors, failure to regain compliance could reduce trading liquidity and make shares harder to sell, potentially lowering market price and investor interest. It could also limit Propanc’s ability to raise capital in public markets and affect employee equity incentives—factors that can influence the company’s financing and operations.
• The notice is procedural (not an immediate delisting). The company may appeal any delisting decision and has until June 30, 2026 to cure the deficiency under the initial Nasdaq compliance period. The filing also contains forward-looking statements about the company’s plans and risks.